The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
High iron levels are a known complicator of survival and overall quality of life for patients with PV. On September 20, 2023, the United States Food and Drug Administration granted fast-track designation to MWTX-003, an investigational anti-transmembrane serine protease 6 (TMPRSS6) monoclonal antibody designed to increase hepcidin levels and, thereby, reduce serum iron levels in patients with polycythemia vera (PV).
Preclinical data have highlighted strong pharmacodynamic effects, with a single dose resulting in a 70% reduction in serum iron levels for 21 days. Moreover, a related β-thalassemia clinical model demonstrated a 4-fold increase in hepcidin levels, a 60–65% reduction in serum and liver iron, increased red blood cell production, and a decrease in spleen weight. A phase I proof-of-mechanism trial is to begin in the second half of 2023. Further plans for a phase 1b/2a proof-of-concept study evaluating the safety and pharmacokinetic profile of MWTX-003 in patients with PV are also in place.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?